Related Experiment Video
Updated: Dec 20, 2025

Measurement of Tactile Allodynia in a Murine Model of Bacterial Prostatitis
Published on: January 16, 2013
MicroRNA-155 deficiency attenuates inflammation and oxidative stress in experimental autoimmune prostatitis in a
Xian Fu1, Hua-Dong He1, Chang-Jiu Li2
1Department of Urology, Affiliated Hangzhou First People's Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Abstract:
To explore the mechanism of microRNA-155 (miR-155) deficiency, protecting against experimental autoimmune prostatitis (EAP) in a toll-like receptor 4 (TLR4)-dependent manner. After wild-type (WT) and miR-155-/- mice were injected with complete Freund's adjuvant and prostate antigen to establish EAP model, half were randomly selected for injection with lipopolysaccharide (LPS, a TLR4 ligand). The following experiments were then performed: von Frey filaments, hematoxylin-eosin (HE) staining, real time quantitative polymerase chain reaction (qRT-PCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA). And the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) and the level of Malondialdehyde (MDA) were detected by corresponding kits.miR-155-/- mice with prostatitis exhibited the attenuated pelvic tactile allodynia/hyperalgesia and the suppressed TLR4/nuclear factor-kappa B (NF-κB) pathway as compared with the WT mice with prostatitis. In addition, LPS enhanced the upregulation of miR-155 and the activation of the TLR4/NF-κB pathway in the prostatic tissues of WT mice with EAP. Furthermore, prostatitis mice had aggravated inflammation scores accompanying the increased interleukin (IL)-1β, tumor necrosis factor-α, IL-6, interferon-γ, IL-12, and MDA in prostatic tissues with the decreased IL-10, SOD and GSH-Px, and the unaltered IL-4. Compared with the mice from the WT + EAP group and the miR-155-/- + EAP + LPS group, mice from the miR-155-/- + EAP group had decreased inflammation and oxidative stress. miR-155 deficiency ameliorated pelvic tactile allodynia/hyperalgesia in EAP mice and improved inflammation and oxidative stress in prostatic tissues in a TLR4-dependent manner involving NF-κB activation, thereby exerting a therapeutic effect in chronic prostatitis treatment.
Insights
MicroRNA-155 deficiency protects against experimental autoimmune prostatitis by reducing inflammation and oxidative stress via the toll-like receptor 4 pathway. This suggests a potential therapeutic strategy for chronic prostatitis.
Area of Science:
- Immunology
- Molecular Biology
- Urology
Background:
- Experimental autoimmune prostatitis (EAP) is an inflammatory condition.
- MicroRNA-155 (miR-155) role in inflammation is complex and requires further elucidation.
- Toll-like receptor 4 (TLR4) signaling is implicated in inflammatory processes.
Purpose of the Study:
- To investigate the protective mechanism of miR-155 deficiency in EAP.
- To determine the involvement of the TLR4 pathway in miR-155's protective effects.
- To explore the therapeutic potential of modulating miR-155 in chronic prostatitis.
Main Methods:
- EAP model established in wild-type (WT) and miR-155 knockout (miR-155-/-) mice.
- Administration of lipopolysaccharide (LPS) to assess TLR4 ligand effects.
- Assessment of pain (von Frey filaments), inflammation (HE staining), gene/protein expression (qRT-PCR, Western blotting, ELISA), and oxidative stress markers (SOD, GSH-Px, MDA).
Main Results:
- miR-155-/- mice with EAP showed reduced pain, inflammation, and suppressed TLR4/NF-κB pathway activation compared to WT mice.
- LPS treatment upregulated miR-155 and activated the TLR4/NF-κB pathway in WT mice with EAP.
- miR-155 deficiency decreased pro-inflammatory cytokines (IL-1β, TNF-α, IL-6, IFN-γ, IL-12) and MDA, while increasing anti-inflammatory IL-10, SOD, and GSH-Px.
Conclusions:
- miR-155 deficiency ameliorates pain and reduces inflammation and oxidative stress in EAP.
- The protective effect is mediated through the TLR4/NF-κB signaling pathway.
- Targeting miR-155 offers a potential therapeutic strategy for chronic prostatitis.

